S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:AGEN - Agenus Stock Price, Forecast & News

$3.66
0.00 (0.00 %)
(As of 02/17/2020 02:23 PM ET)
Today's Range
$3.55
Now: $3.66
$3.72
50-Day Range
$3.50
MA: $3.79
$4.16
52-Week Range
$2.13
Now: $3.66
$4.57
Volume609,702 shs
Average Volume1.09 million shs
Market Capitalization$502.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.78 million
Book Value($1.45) per share

Profitability

Net Income$-159,690,000.00
Net Margins-107.15%

Miscellaneous

Employees294
Market Cap$502.74 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.


Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. The biotechnology company earned $19.94 million during the quarter, compared to analysts' expectations of $15.60 million. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus.

What price target have analysts set for AGEN?

1 brokers have issued 12-month price targets for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' stock price to reach $6.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Agenus.

What is the consensus analysts' recommendation for Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.

Has Agenus been receiving favorable news coverage?

Media stories about AGEN stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agenus earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Agenus.

Are investors shorting Agenus?

Agenus saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 11,730,000 shares, an increase of 15.3% from the December 31st total of 10,170,000 shares. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is presently 9.5 days. Approximately 11.2% of the company's stock are sold short. View Agenus' Current Options Chain.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
  • Dr. Jennifer Buell, Chief Operating Officer
  • Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
  • Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
  • Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.86%), Oracle Investment Management Inc. (2.02%), Panagora Asset Management Inc. (0.69%), Charles Schwab Investment Management Inc. (0.52%), Bank of New York Mellon Corp (0.34%) and Oxford Asset Management LLP (0.33%). View Institutional Ownership Trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Chicago Equity Partners LLC, Bank of America Corp DE, Charles Schwab Investment Management Inc., Strs Ohio, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank and Bank of New York Mellon Corp. View Insider Buying and Selling for Agenus.

Which institutional investors are buying Agenus stock?

AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Oracle Investment Management Inc., Captrust Financial Advisors, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, Hussman Strategic Advisors Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.66.

How big of a company is Agenus?

Agenus has a market capitalization of $502.74 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.

What is Agenus' official website?

The official website for Agenus is http://agenusbio.com/.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]


MarketBeat Community Rating for Agenus (NASDAQ AGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  414 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  735
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel